CompletedPhase 1NCT02262455
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Studying Clear cell adenocarcinoma of the ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Santa Maria Biotherapeutics
- Principal Investigator
- Willis Navarro, MDSanta Maria Biotherapeutics
- Intervention
- STM 434(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2017
Study locations (4)
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Sarah Cannon Research Institute, Nashville, Tennessee, United States
- South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02262455 on ClinicalTrials.govOther trials for Clear cell adenocarcinoma of the ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06677190Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic OriginDana-Farber Cancer Institute
- RECRUITINGPHASE1, PHASE2NCT06065462Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100M.D. Anderson Cancer Center
- RECRUITINGNCT06279104A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the OvaryTongji Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05296512Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerElizabeth K. Lee MD
- ACTIVE NOT RECRUITINGPHASE2NCT05032040A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesXencor, Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT05226507A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerNuvectis Pharma, Inc.
- RECRUITINGPHASE1, PHASE2NCT04104776A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE2NCT03348631Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial CancerNational Cancer Institute (NCI)